1l5s: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="1l5s" size="450" color="white" frame="true" align="right" spinBox="true" caption="1l5s, resolution 2.10Å" /> '''Human liver glycoge...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1l5s.gif|left|200px]]<br />
[[Image:1l5s.gif|left|200px]]<br /><applet load="1l5s" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1l5s" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1l5s, resolution 2.10&Aring;" />
caption="1l5s, resolution 2.10&Aring;" />
'''Human liver glycogen phosphorylase complexed with uric acid, N-Acetyl-beta-D-glucopyranosylamine, and CP-403,700'''<br />
'''Human liver glycogen phosphorylase complexed with uric acid, N-Acetyl-beta-D-glucopyranosylamine, and CP-403,700'''<br />


==Overview==
==Overview==
Human liver glycogen phosphorylase (HLGP) catalyzes the breakdown of, glycogen to maintain serum glucose levels and is a therapeutic target for, diabetes. HLGP is regulated by multiple interacting allosteric sites, each, of which is a potential drug binding site. We used surface plasmon, resonance (SPR) to screen for compounds that bind to the purine allosteric, inhibitor site. We determined the affinities of a series of compounds and, solved the crystal structures of three representative ligands with K(D), values from 17-550 microM. The crystal structures reveal that the, affinities are partly determined by ligand-specific water-mediated, hydrogen bonds and side chain movements. These effects could not be, predicted; both crystallographic and SPR studies were required to, understand the important features of binding and together provide a basis, for the design of new allosteric inhibitors targeting this site.
Human liver glycogen phosphorylase (HLGP) catalyzes the breakdown of glycogen to maintain serum glucose levels and is a therapeutic target for diabetes. HLGP is regulated by multiple interacting allosteric sites, each of which is a potential drug binding site. We used surface plasmon resonance (SPR) to screen for compounds that bind to the purine allosteric inhibitor site. We determined the affinities of a series of compounds and solved the crystal structures of three representative ligands with K(D) values from 17-550 microM. The crystal structures reveal that the affinities are partly determined by ligand-specific water-mediated hydrogen bonds and side chain movements. These effects could not be predicted; both crystallographic and SPR studies were required to understand the important features of binding and together provide a basis for the design of new allosteric inhibitors targeting this site.


==Disease==
==Disease==
Line 11: Line 10:


==About this Structure==
==About this Structure==
1L5S is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with NBG, PLP, 700, URC and MRD as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phosphorylase Phosphorylase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.1.1 2.4.1.1] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1L5S OCA].  
1L5S is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=NBG:'>NBG</scene>, <scene name='pdbligand=PLP:'>PLP</scene>, <scene name='pdbligand=700:'>700</scene>, <scene name='pdbligand=URC:'>URC</scene> and <scene name='pdbligand=MRD:'>MRD</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Phosphorylase Phosphorylase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.1.1 2.4.1.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1L5S OCA].  


==Reference==
==Reference==
Line 18: Line 17:
[[Category: Phosphorylase]]
[[Category: Phosphorylase]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Carty, M.D.]]
[[Category: Carty, M D.]]
[[Category: Culp, J.]]
[[Category: Culp, J.]]
[[Category: Danley, D.E.]]
[[Category: Danley, D E.]]
[[Category: Day, Y.S.N.]]
[[Category: Day, Y S.N.]]
[[Category: Ekstrom, J.L.]]
[[Category: Ekstrom, J L.]]
[[Category: Fletterick, R.J.]]
[[Category: Fletterick, R J.]]
[[Category: Gibbs, E.M.]]
[[Category: Gibbs, E M.]]
[[Category: Hoover, D.J.]]
[[Category: Hoover, D J.]]
[[Category: Myszka, D.G.]]
[[Category: Myszka, D G.]]
[[Category: Pauly, T.A.]]
[[Category: Pauly, T A.]]
[[Category: Rath, V.L.]]
[[Category: Rath, V L.]]
[[Category: Soeller, W.C.]]
[[Category: Soeller, W C.]]
[[Category: Treadway, J.L.]]
[[Category: Treadway, J L.]]
[[Category: 700]]
[[Category: 700]]
[[Category: MRD]]
[[Category: MRD]]
Line 39: Line 38:
[[Category: purine site]]
[[Category: purine site]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 17:57:08 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 13:41:37 2008''